Argyle Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History

Argyle Capital Partners’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$404K	Sell	6,479 -149	-2%	-$9.42K	0.25%	103
2026 Q2	$382K	Buy	6,628 +146	+2%	+$8.38K	0.24%	109
2026 Q1	$393K	Sell	6,482 -3,317	-34%	-$193K	0.28%	99
2025 Q4	$529K	Sell	9,799 -473	-5%	-$22.8K	0.39%	80
2025 Q3	$463K	Buy	10,272 +687	+7%	+$32.1K	0.33%	89
2025 Q2	$444K	Sell	9,585 -3,764	-28%	-$185K	0.37%	80
2025 Q1	$814K	Sell	13,349 -836	-6%	-$48.7K	0.7%	50
2024 Q4	$802K	Buy	+14,185	New	+$793K	0.69%	49

Other funds holding BMY

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pzena Investment Management New York $34.1B AUM 26.62% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return

Nordea Investment Management Stockholm, Sweden $127B AUM 33.25% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Argyle Capital Partners's BMY Position: Q3 2026 in Review

Argyle Capital Partners reduced its Bristol-Myers Squibb (BMY) stake by 2.2% in Q3 2026, selling an estimated $9.42K and leaving 6,479 shares worth $404K. The position accounts for 0.25% of the portfolio, ranked #103.

Argyle Capital Partners first reported a position in BMY in Q4 2024 and has held it in 8 quarters since. The position peaked at $814K in Q1 2025. 1,763 funds tracked by Wall St. Rank hold BMY as of Q3 2026.

Argyle Capital Partners held 6,479 shares of Bristol-Myers Squibb worth $404K as of Q3 2026.
Argyle Capital Partners sold 149 Bristol-Myers Squibb shares in Q3 2026, an estimated $9.42K.
Bristol-Myers Squibb made up 0.25% of Argyle Capital Partners's portfolio in Q3 2026, its #103 holding.
Argyle Capital Partners first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 8 quarters since.
Argyle Capital Partners's Bristol-Myers Squibb position peaked at $814K in Q1 2025.
1,763 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q3 2026.

Based on Argyle Capital Partners's 13F filing for Q3 2026, filed 23 Oct 2026.